| Patents for A61P 17 - Drugs for dermatological disorders (106,455) |
|---|
| 01/03/2003 | WO2003000194A2 Thienopyridine and thienopyrimidine anticancer agents |
| 01/03/2003 | WO2003000185A2 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/03/2003 | WO2002087596A3 Use of azithromycin for the manufacture of a medicament for treatment of non-infective inflammatory diseases |
| 01/03/2003 | WO2002083667A3 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 01/03/2003 | WO2002080914A3 Use of substituted imidazo[1,2-a]-pyridine compounds as medicaments |
| 01/03/2003 | WO2002066020A3 Modulation of gsk-3beta activity and its different uses |
| 01/03/2003 | WO2002055676A3 Method for processing dendritic cells and for activating macrophages with ru 41740 |
| 01/03/2003 | WO2002051828A3 Novel c-glycoside derivatives and use thereof |
| 01/03/2003 | WO2002047673A3 Methods and compositions to treat conditions associated with neovascularization |
| 01/03/2003 | WO2002046170A8 Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto |
| 01/03/2003 | WO2002045702A3 Tricyclic therapeutics for chemokine mediated diseases |
| 01/03/2003 | WO2002016557A3 Tissue engineering scaffolds promoting matrix protein production |
| 01/03/2003 | WO2002012501A3 Anti-dual integrin antibodies, compositions, methods and uses |
| 01/03/2003 | WO2002012500A3 Anti-il-12 antibodies, compositions, methods and uses |
| 01/03/2003 | WO2002010387A3 G-protein coupled receptors |
| 01/03/2003 | WO2002002603A3 Protein modification and maintenance molecules |
| 01/03/2003 | WO2002000727A3 Gp286 nucleic acids and polypeptides |
| 01/03/2003 | WO2001089502A3 Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes |
| 01/03/2003 | WO2001081581A9 Compositions and methods for the therapy and diagnosis of acne vulgaris |
| 01/03/2003 | CA2489623A1 Atopy |
| 01/03/2003 | CA2451625A1 Substituted n-acyl-aniline derivatives, the preparation thereof and the use thereof as pharmaceutical compositions |
| 01/03/2003 | CA2451138A1 Remedies for eosinophilic diseases |
| 01/03/2003 | CA2450969A1 Nucleic acid-associated proteins |
| 01/03/2003 | CA2450921A1 Protein modification and maintenance molecules |
| 01/03/2003 | CA2450562A1 Tyrosine kinase inhibitors |
| 01/03/2003 | CA2450478A1 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/03/2003 | CA2449844A1 Naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| 01/02/2003 | WO2002002529A1 Bicyclic lactams and sulfonamides with 5-ht1a-affinity and use thereof for preventing and treating cerebral ischaemia |
| 01/02/2003 | US20030004499 Method and apparatus for the photomodulation of living cells |
| 01/02/2003 | US20030004351 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors |
| 01/02/2003 | US20030004350 Pyrrolo(2,3-b)pyridine derivatives; anticancer and antiproliferative agents |
| 01/02/2003 | US20030004340 Skin disorders; gastrointestinal disorders |
| 01/02/2003 | US20030004324 31 human secreted proteins |
| 01/02/2003 | US20030004197 Composition with a continuous aqueous phase containing L-2-oxothiazoldine-4-carboxylic acid |
| 01/02/2003 | US20030004196 Antiinflamamtory agents; autoimmune disease |
| 01/02/2003 | US20030004193 Immunomodulators; antiinflammatory agents |
| 01/02/2003 | US20030004174 Antiinflammatory agents, anticancer agents, antihistamines, central nervous system disorders |
| 01/02/2003 | US20030004165 Polyazanaphthalene compounds and pharmaceutical use thereof |
| 01/02/2003 | US20030004164 Anticancer agents; autoimmune diseases |
| 01/02/2003 | US20030004161 Anticancer agents; autoimmune diseases |
| 01/02/2003 | US20030004156 Anticholesterol agents; cardiovascular disorders; antidiabetic agents; antiproliferative agents |
| 01/02/2003 | US20030004153 Novel heteroaryl-diazabicycloalkanes |
| 01/02/2003 | US20030004151 Cyclic derivatives as modulators of chemokine receptor activity |
| 01/02/2003 | US20030004144 Anticancer agents; skin disorders |
| 01/02/2003 | US20030004137 Muscle relaxants, controlling immunology, strokes, antidiabetic agents |
| 01/02/2003 | US20030004131 Oenothein medicaments |
| 01/02/2003 | US20030004118 Antibiotic/benzoyl peroxide dispenser |
| 01/02/2003 | US20030004117 Methods for inhibiting angiogenesis |
| 01/02/2003 | US20030004110 Therapeutic compositions and methods for enhancing angiogenesis |
| 01/02/2003 | US20030004106 Interleukin-1 receptor antagonist-related molecules and uses thereof |
| 01/02/2003 | US20030003576 Peripheral blood fibrocytes differentiation pathway and migration to wound sites |
| 01/02/2003 | US20030003532 Novel nucleic acid sequences encoding human slit-, megf-, and roundabout-like polypeptides |
| 01/02/2003 | US20030003462 Novel human interleukin-like proteins and polynucleotides encoding them |
| 01/02/2003 | US20030003169 Prepared by fermenting an aqueous Glycine max (L.) extract with at least one lactic acid bacteria together with at least one yeast |
| 01/02/2003 | US20030003164 Use of dictyotal extracts in the production of a topical composition |
| 01/02/2003 | US20030003163 For restoration and maintenance of gingival and periodontal health; antiplaque/antitar agents; mouthwash |
| 01/02/2003 | US20030003123 A substance/species active with respect to the trophicity of the cutaneous nerves and/or neurostimulant and/or neuroactivator and/or neuromediator, formulated into cosmetically, or dermatologically acceptable vehicle, diluent |
| 01/02/2003 | US20030003116 Skin care agent and method of skin care |
| 01/02/2003 | US20030003082 Use of poly-Glu,Tyr and T cells treated therewith for neuroprotective therapy |
| 01/02/2003 | US20030003077 A genetic engineered adenoviral vector contains an adenoviral genome from which the open reading frames E1 and/or E3 were deleted and a therapeutic gene or a DNA sequence that encodes for therapeutic proteins useful in fibrosis treatment |
| 01/02/2003 | US20030003071 N-methyltaurine as an active ingredient; giving hair fitness and body, and giving hair a feeling of volume |
| 01/02/2003 | EP1270599A1 Salmon-origin chondroitin sulfate |
| 01/02/2003 | EP1270595A1 Gene recombinant antibody and its fragment |
| 01/02/2003 | EP1270044A2 Wound healing biomarkers |
| 01/02/2003 | EP1270013A1 Topical wound healing compositions comprising hyaluronic acid and a serine protease inhibitor |
| 01/02/2003 | EP1269992A1 Compositions comprising quaternary ammonium compounds |
| 01/02/2003 | EP1269990A1 Cosmetic or dermatological composition comprising acylaminoamide derivatives |
| 01/02/2003 | EP1269989A1 Cosmetic or dermatological composition comprising acylaminoamide derivatives |
| 01/02/2003 | EP1269988A1 Cosmetic or dermatological composition comprising acylaminoamide derivatives |
| 01/02/2003 | EP1269986A2 Compositions comprising a compound of low solubility and a lipophilic amino acid derivative, and corresponding uses and processes |
| 01/02/2003 | EP1269984A1 Cosmetic and/or dermatological andor pharmaceutical composition for topical application containing at least one compound inhibiting 3-beta-HSD enzyme |
| 01/02/2003 | EP1269983A1 Use of 1,2-Decanediol against germs which cause body malodour |
| 01/02/2003 | EP1269979A1 Aromatic amide, sulfonamide or carbamate acrylonitrile derivatives and photoprotective cosmetic compositions containing them |
| 01/02/2003 | EP1269973A1 Hair growth stimulant compositions |
| 01/02/2003 | EP1269972A1 Hair growth stimulant compositions with sustained action |
| 01/02/2003 | EP1269198A2 Identification of mast/basophil activation inhibitors |
| 01/02/2003 | EP1268802A2 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 01/02/2003 | EP1268798A2 Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains |
| 01/02/2003 | EP1268783A2 Anti-angiogenic and anti-tumor properties of matin and other laminin domains |
| 01/02/2003 | EP1268778A1 Materials and methods relating to a novel splice variant of a na + dependent glutamate transporter |
| 01/02/2003 | EP1268558A1 Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect |
| 01/02/2003 | EP1268554A2 Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
| 01/02/2003 | EP1268549A2 Method of identifying inhibitors of tie-2 |
| 01/02/2003 | EP1268544A2 Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof |
| 01/02/2003 | EP1268543A2 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| 01/02/2003 | EP1268503A1 O-glucosylated benzamide sglt2 inhibitors and method |
| 01/02/2003 | EP1268502A1 O-aryl glucoside sglt2 inhibitors and method |
| 01/02/2003 | EP1268487A1 Tricyclic protein kinase inhibitors |
| 01/02/2003 | EP1268481A2 Kinase inhibitors as therapeutic agents |
| 01/02/2003 | EP1268480A1 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors |
| 01/02/2003 | EP1268476A1 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors |
| 01/02/2003 | EP1268475A1 Novel benzosultam oxazolidinone antibacterial agents |
| 01/02/2003 | EP1268474A2 Substituted 1,3-thiazole compounds, their production and use |
| 01/02/2003 | EP1268472A1 3-aminopyrazole inhibitors of cyclin dependent kinases |
| 01/02/2003 | EP1268471A1 N-heterocyclic derivatives as nos inhibitors |
| 01/02/2003 | EP1268465A1 Triarylimidazole derivatives as cytokine inhibitors |
| 01/02/2003 | EP1268455A2 Piperazine derivatives |
| 01/02/2003 | EP1268453A1 Estrogen agonist/antagonist metabolites |
| 01/02/2003 | EP1268448A1 Bicyclic amine derivatives as inhibitors of class 1 receptor tyrosine kinases |
| 01/02/2003 | EP1268445A1 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases |